Open AccessCorrection: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Author(s) -
Sunkyu Kim,
Ralph Tiedt,
Alice Loo,
Thomas Horn,
Scott Delach,
Steven Kovats,
Kristy Haas,
Barbara Schacher Engstler,
Alexander Cao,
Maria Pinzon-Ortiz,
Iain J. Mulford,
Michael G. Acker,
Rajiv Chopra,
Christopher Brain,
Emmanuelle di Tomaso,
William R. Sellers,
Giordano Caponigro
Publication year - 2020
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.27407
Subject(s) - kinase , cyclin dependent kinase , cancer research , medicine , cyclin dependent kinase 6 , cancer , pharmacology , chemistry , cell cycle , biochemistry